The SARS COV2 and other SARS viruses employ a heavily glycosylated spike S protein (Watanabe et al. 2020; Shajahan et al. 2020a) to bind to the ACE2 cellular receptor, also heavily glycosylated (Shajahan et al. 2020b), on host cells. Historically, there is abundant information of glycosylation inhibitors for antiviral activity to stimulate their investigation for COVID19 treatment. While there are certain to be side effects by interfering systematically with glycosylation, a short-term dose of primers, decoys or glycosylation inhibitors might be sufficient to stop or slow the COVID19 infection cycle with minimal or temporary side effects. For example, castanospermine derivative celgosivir (6-O-butanoylcastanospermine) (Sels et al. 1999) and Miglitol, Miglustat (N-butyl −1-deoxynojirimycin) (Campo et al. 2013; Zamoner et al. 2019) are already FDA approved for type 2 diabetes and Gaucher’s disease (Rosenbloom and Weinreb 2013), passing safety and effectivity phases. This article is to stimulate repurpose testing of these already-approved compounds and others for COVID19 therapeutics.

中文翻译：

---

在 COVID19 中重新检查糖基化抑制剂、模拟物、引物和糖基化诱饵作为抗病毒药和抗炎药的案例。

SARS COV2 和其他 SARS 病毒使用高度糖基化的刺突 S 蛋白（渡边等人。2020 年；沙贾汉等人。2020a) 与 ACE2 细胞受体结合，同样高度糖基化（沙贾汉等人。2020b)，在宿主细胞上。从历史上看，有大量关于糖基化抑制剂抗病毒活性的信息，以刺激他们对 COVID19 治疗的研究。虽然系统地干扰糖基化肯定会产生副作用，但短期剂量的引物、诱饵或糖基化抑制剂可能足以阻止或减缓 COVID19 感染周期，而副作用很小或暂时。例如，栗精胺衍生物西戈斯韦（6-O-丁酰基栗精胺）（塞尔斯等人。1999) 和 Miglitol, Miglustat (N-丁基 -1-脱氧野尻霉素) (坎波等人。2013年；扎蒙纳等人。2019 年）已被 FDA 批准用于 2 型糖尿病和戈谢病（Rosenbloom 和 Weinreb 2013），通过了安全性和有效性阶段。本文旨在刺激对这些已获批准的化合物和其他用于 COVID19 疗法的化合物进行重新测试。